Two-week chemo combo for HER2-negative advanced breast cancer
Part of Cancer clinical trials.
This trial tests a two-week schedule of two chemotherapy drugs (vinorelbine and liposomal doxorubicin) for people with HER2-negative advanced breast cancer who have already tried certain other chemotherapies. The goal is to see if this combo works well and is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have HER2-negative advanced breast cancer (confirmed by specific tests).
- You have already received taxane and anthracycline chemotherapy, and at least 2 lines of chemotherapy for metastatic disease.
- You have at least one tumor that can be measured on scans.
- Your cancer has gotten worse or you couldn't tolerate prior treatments.
- Your heart, liver, kidney, and blood counts are within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of radiation therapy, immunotherapy, and a drug that blocks blood vessel growth for advanced HER2-negative breast cancer that has spread. It is for patients whose cancer has worsened after at least two prior treatments.
This phase 3 trial compares two pre-surgery treatment plans for people with HER2-positive invasive breast cancer that has spread to nearby lymph nodes. It aims to see which plan works better to shrink the tumor before surgery and improve outcomes.
This trial tests a combination of targeted drugs (Initumab and Pyrrotinib) plus chemotherapy before surgery for HER2-positive breast cancer. It compares different treatment lengths to see which is more effective and safe.
This trial tests two study drugs, HLX22 and HLX87, together for people with HER2-positive breast cancer that has spread or come back. It may be an option if you haven't yet had chemotherapy or HER2-targeted therapy for advanced disease.
This trial tests whether inetetamab combined with pyrotinib and vinorelbine works better and is safe for adults with HER2-positive advanced breast cancer. You may be considered if standard options have not removed the cancer with surgery and your body can handle chemotherapy and HER2-targeting medicines.
This trial studies a faster, higher-frequency chemotherapy schedule given before surgery for HER2-negative breast cancer. It aims to see if this approach works better and is safe for the patient’s cancer stage.
Hear when a new Her2-negative Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.